CXCR3 and neoplasm: The tumor volume and weight in immunocompetent animals treated with AMG487 did not demonstrate a significant difference compared to the control animals (Figure 6G–J), suggesting that the CXCR3 antagonist does not inhibit tumor growth in an immunocompetent model, and may have effects on the immune tumor microenvironment that offset the tumor proliferative effects of CXCR3 ligands.